Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy

1293.2.00049 Boehringer Ingelheim Investigational Site, Olomouc

1293.2.00024 Boehringer Ingelheim Investigational Site, Uherské Hradiště

1293.2.00028 Boehringer Ingelheim Investigational Site, Zlín

1293.2.00015 Boehringer Ingelheim Investigational Site, Bad Kreuznach

1293.2.00010 Boehringer Ingelheim Investigational Site, Berlin

1293.2.00013 Boehringer Ingelheim Investigational Site, Berlin

1293.2.00043 Boehringer Ingelheim Investigational Site, München

1293.2.00012 Boehringer Ingelheim Investigational Site, Zerbst

1293.2.00031 Boehringer Ingelheim Investigational Site, Amsterdam

1293.2.00032 Boehringer Ingelheim Investigational Site, Leeuwarden

1293.2.00038 Boehringer Ingelheim Investigational Site, Leiden

1293.2.00040 Boehringer Ingelheim Investigational Site, Sneek

1293.2.00001 Boehringer Ingelheim Investigational Site, Grafton Auckland NZ

1293.2.00039 Boehringer Ingelheim Investigational Site, Bialystok

1293.2.00034 Boehringer Ingelheim Investigational Site, Bydgoszcz

1293.2.00041 Boehringer Ingelheim Investigational Site, Bydgoszcz

1293.2.00025 Boehringer Ingelheim Investigational Site, Lublin

1293.2.00050 Boehringer Ingelheim Investigational Site, Poznan

1293.2.00023 Boehringer Ingelheim Investigational Site, Warsaw

1293.2.00026 Boehringer Ingelheim Investigational Site, Warsaw

1293.2.00021 Boehringer Ingelheim Investigational Site, A Coruña

1293.2.00017 Boehringer Ingelheim Investigational Site, Barcelona

1293.2.00022 Boehringer Ingelheim Investigational Site, Granada

1293.2.00016 Boehringer Ingelheim Investigational Site, La Laguna (Sta Cruz Tenerife)

1293.2.00020 Boehringer Ingelheim Investigational Site, Santiago de Compostela